PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsType 1 diabetes mellitus
MeSH D003922 - type 1 diabetes mellitus
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D003920:Diabetes mellitus
11 Companies
14 Drugs
$
Success rate
D001327:Autoimmune diseases
1 Company
1 Drug
$
Success rate
D003922: 
Type 1 diabetes mellitus
10 Companies
9 Drugs
$
Success rate
D014929:Wolfram syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
BioconInsulin glargine Semglee  2021-07-28   
MylanInsulin glargine Semglee  2020-06-11   
AstraZenecaPramlintide Symlin  2005-03-16 $33 M Q3/18-Q2/19 
SanofiInsulin lispro Admelog  2017-12-11   
Insulin lispro Insulin lispro Sanofi  2017-07-19   
Insulin glargine Lantus  2000-04-20   
Lixisenatide, Insulin glargine Soliqua  2016-11-21   
Lixisenatide, Insulin glargine Suliqua  2017-01-11   
Insulin glargine Toujeo  2015-02-25   
Insulin glargine Toujeo (previously Optisulin)  2000-06-26   
Merck & CoInsulin glargine Lusduna  2017-01-03   
Eli LillyInsulin glargine Abasaglar (previously Abasria)  2014-09-09   
Insulin glargine Basaglar  2015-12-16 $685.2 M Q4/23-Q3/24 
Insulin lispro Humalog  1996-06-14 $2,071.6 M Q4/23-Q3/24 
Insulin lispro Humalog Mix  1999-12-22   
Insulin lispro Liprolog  1997-05-07   
Insulin lispro Lyumjev  2020-06-15   
Insulin lispro Lyumjev (previously Liumjev)  2020-03-24   
Insulin glargine Rezvoglar  2021-12-17   
ViatrisInsulin glargine Semglee  2018-03-23   
Novo NordiskInsulin aspart, Insulin degludec Ryzodeg  2015-09-25   
Insulin degludec Tresiba  2015-09-25   
Liraglutide, Insulin degludec Xultophy  2016-11-21   
Guidehouse GermanySotagliflozin Zynquista  2019-04-26   
Provention BioTeplizumab Tzield  2022-11-17   
Clinical Trials
Historical Success Rate
Phase 1
68%
71/104
Phase 2
44%
62/140
Phase 3
49%
38/77
Approved: 6Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Biocon
Insulin glargine,
Lysine,
Viaject,
Lyspro
Mylan
Insulin glargine,
Viaject,
Lyspro
AstraZeneca
Pramlintide,
Angiotensin ii,
Enoblituzumab,
Ademetionine,
Nadide,
Retinol,
AZD1656,
Manitol,
Viaject,
Lyspro,
Sglt2,
Farxiga,
Arm1,
Arm2,
Bolus,
Mydfrin
Sanofi
Insulin lispro,
Lixisenatide,
Insulin glargine,
Mycophenolate sodium,
Docusate,
Lampalizumab,
Lenograstim,
Ademetionine,
Sodium chloride,
Bevifimod,
Insulatard,
Ratg,
Viaject,
Csii,
Lyspro,
SAR438544,
Sglt2,
Gcsf,
Hsct,
Sar341402,
Arm2,
Bolus,
Intraperitoneal,
Mydfrin
Merck & Co
Insulin glargine,
Losartan,
Angiotensin ii,
Benzocaine,
Antithrombin iii,
Ademetionine,
Terfenadine,
Sodium lactate,
Microcrystalline cellulose,
Viaject,
Lyspro
Eli Lilly
Insulin lispro,
Insulin glargine,
Benzocaine,
Enoblituzumab,
Ruboxistaurin,
Ademetionine,
Sodium chloride,
Sodium lactate,
ADOMEGLIVANT,
Aspartame,
Muromonab-cd3,
Microcrystalline cellulose,
Diluent,
Insulatard,
Ly333531,
LY3532226,
LY3938577,
Viaject,
Csii,
Lyspro,
Sglt2,
Bolus,
Demand
Novo Nordisk
Insulin aspart,
Liraglutide,
Insulin degludec,
Salicylic acid,
Benzocaine,
Albumin,
Ademetionine,
Sodium chloride,
Aspartame,
Bevifimod,
Insulatard,
Viaject,
Csii,
Biasp30,
Lyspro,
Sglt2,
Farxiga,
Nn1952,
Arm1,
Idegasp,
Arm2,
Bolus
Provention Bio
Teplizumab,
Ademetionine
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use